- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03735017
Virtual Reality Walking for Neuropathic Pain in Spinal Cord Injury
Immersive Virtual Walking Treatment for Neuropathic Pain in Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with complete paraplegic spinal cord injury who report chronic neuropathic pain
- Individuals with persistent spinal cord injury neuropathic pain
- More than one - year post injury
- Stable medication regimen for the past month
Exclusion Criteria:
- Conditions that impair movement of the arms
- Significant cognitive impairment as suggested by apparent incomprehension of screening questions as judged by the evaluator
- For those for whom voluntary arm movement would cause sufficient discomfort (>4/10) that could prevent trial completion will be excluded from participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Non-Interactive
Participants will receive non-interactive virtual reality walking sessions.
|
Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart. |
Experimental: Interactive
Participants will receive interactive virtual reality walking sessions.
|
Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Intensity as assessed by Numeric Rating Scale
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
The Numeric Rating Scale (NRS) measures pain intensity measured via 0-10 numeric rating scale. Range of scores: 0-10 |
Baseline - Final assessment (average 1 week post treatment)
|
Neuropathic Pain Qualities as assessed by Neuropathic Pain Scale
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
The Neuropathic Pain Scale (NPS) was designed to assess the distinct pain qualities associated with neuropathic pain.The NPS consists of 10 items. Seven of the 10 items contain the words intense, sharp, hot, dull, cold, and itchy to characterize the patient's pain and the word sensitive to describe the patient's pain reaction to light touch or clothing.One item describes the time quality of the pain (all the time or some of the time). The ninth item describes the overall unpleasantness of the pain, whereas the last item indicates the intensity of the deep and surface pain. In the NPS each item is rated separately. All the items are rated 0-10 scale, with higher score indicative of more neuropathic pain for each type of respective pain. Range of scores: 0-10 for each item. |
Baseline - Final assessment (average 1 week post treatment)
|
Neuropathic Pain Diagnosis as assessed by Doleur Neuropatique 4
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Doleur Neuropatique 4 is a 10 item survey that evaluates neuropathic pain following central and neurological lesions. It has components of how the pain feels to the patient (e.g. burning, cold, electrical shocks, tingling, hypoaesthesia). Responses to each item is yes or no, with each yes response equaling one point. Range of scores: 0-10. 4/10 and greater indicate neuropathic pain. |
Baseline - Final assessment (average 1 week post treatment)
|
Pain Interference specific to spinal cord injury as assessed by International Spinal Cord Injury Pain Basic Data Set version 2.0
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Pain interference measured International Spinal Cord Injury Pain Basic Data Set version 2.0 interference items. There are 3 pain interference items using a 0-10 numeric rating scale for each item. Items can be assessed by summing the score or by individual assessment of items. Summed range of scores: 0-30. Individual item range of scores: 0-10 |
Baseline - Final assessment (average 1 week post treatment)
|
Pain Interference as assessed by Brief Pain Inventory
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Pain interference measured by Brief Pain Inventory interference items. 7 items each use a 0-10 scale. Item scores may be assessed individually, or by taking the average score of all items. Range of Scores: 0-10. Increased scores indicate higher levels of interference due to pain. |
Baseline - Final assessment (average 1 week post treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Treatment Evaluation as assessed by the Ease of Usefulness, Satisfaction, and Ease of Use Questionnaire
Time Frame: Final assessment (average 1 week post treatment)
|
Ease of Usefulness, Satisfaction, and Ease of use Questionnaire is a 30 item survey. Subscales include: treatment's usefulness, ease of use, ease of learning, and satisfaction. Each item is presented on a 7-point Likert scale. Each subscale is calculated by averaging all items in subscale. Range of scores for each subscale: 1-7 |
Final assessment (average 1 week post treatment)
|
Patient Treatment Evaluation as assessed by the Patient Global Impression of Change Scale
Time Frame: Final assessment (average 1 week post treatment)
|
Patient treatment evaluation is assessed by the Patient Global Impression of Change. This is a one item 7 point Likert item assessing improvement of the participants overall status. Range of scores: 1-7 |
Final assessment (average 1 week post treatment)
|
Patient Treatment Evaluation as assessed by the Modified Treatment Evaluation Inventory
Time Frame: Final assessment (average 1 week post treatment)
|
Patient treatment evaluation is assessed by Treatment Evaluation Inventory. This is a 9 item scale with a 5-point Likert responses for each question. The items are scored by summing all items. Range of scores: 9-45. A higher score indicates greater acceptance of treatment. |
Final assessment (average 1 week post treatment)
|
Patient Treatment Evaluation as assessed by Semi-structured Qualitative Interviewing
Time Frame: Final assessment (average 1 week post treatment)
|
Patient treatment evaluation is assessed by semi-structured interviewing.
Qualitative feedback from participant experience will be assessed by thematic analyses.
|
Final assessment (average 1 week post treatment)
|
Quality of Life and Participation are assessed by the SF-36 Walk-Wheel
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Quality of life and participation are assessed by the SF-Walk Wheel. This is a 36 item assess health concepts which represent basic human values and were relevant to a person's functional status and well-being. The responses are based on a Likert scale. There are the following subscales: Physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Each item is recoded to a preset value between 0-100 per the scoring key. Range of scores: 0-100 for each sub-scale. A higher score defines a more favorable health state. |
Baseline - Final assessment (average 1 week post treatment)
|
Quality of Life is assessed by Satisfaction with Life Scale
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Quality of life is assessed by the Satisfaction with Life Scale. This is a 5 item survey. Response options are a 7-point Likert scale. Items may be assessed individually or by summing items. Range of scores: 5-35. Higher scores indicate more satisfaction in life |
Baseline - Final assessment (average 1 week post treatment)
|
Depression and mood are assessed by the Patient Health Questionnaire -9
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Depression and mood are measured by Patient Health Questionnaire-9. This is a 10 item tool. The first 9 items are a 4-point Likert scale assessing depressive symptoms. The first 9 items are summed to determine depressive symptom severity. Item 10 assesses difficulty dealing with items 1-9. Item 10 is not used in scoring severity. Range of scores: 0-27. Higher scores indicate more depressive symptom severity. |
Baseline - Final assessment (average 1 week post treatment)
|
Perceived Disability is assessed by the Pain Disability Index
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
Perceived Disability measured by a modified Pain Disability Index. The rating scales are designed to measure the degree to which aspects of life are disrupted by chronic pain. This is a 7 item survey with response options of 0-10. Each item may be assessed individually, or by summing all items. Individual item range of scores: 0-10 Total range of scores: 0-70. The higher the index, the greater the person's disability due to pain. |
Baseline - Final assessment (average 1 week post treatment)
|
Absorption is assessed by the Tellegen Absorption Scale
Time Frame: Baseline
|
Tellegen Absorption Scale is a 34-item multi-dimensional measure that assesses imaginative involvement and the tendency to become mentally absorbed in everyday activities. Item responses are on a 5-point Likert scale. Items are summed to score. Range of scores: 0-136. Higher scores indicate greater levels of absorption. |
Baseline
|
Immersive Tendencies are assessed by the Immersive Tendencies Questionnaire
Time Frame: Baseline
|
Immersive Tendencies are assessed by the Immersive Tendencies Questionnaire (ITQ). This is an 18-item survey. Item responses use a 7 point Likert scale. Subscales include: focus, involvement, emotions, and play. Each subscale is scored by summing items. A total score is scored by summing all items. Range of total score: 18-126 Focus range of scores: 5-35 Involvement range of scores: 5-35 Emotions range of scores: 4-28 Play range of scores: 3-21 Higher scores indicate higher immersive tendencies overall and in each sub-scale. |
Baseline
|
fMRI Imaging
Time Frame: Baseline - Final assessment (average 1 week post treatment)
|
We are studying pain by functional Magnetic Resonance Imaging (fMRI) which allows us to identify certain parts of the brain that show how the brain works in controlling pain perception and cognitions.
|
Baseline - Final assessment (average 1 week post treatment)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zina Trost, PhD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 383546
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
Clinical Trials on Non-Interactive Virtual Reality Walking
-
Cairo UniversityRecruiting
-
HaEmek Medical Center, IsraelUnknown
-
National Taiwan University HospitalRecruitingLumbar Spinal StenosisTaiwan
-
University of Massachusetts, LowellSpaulding Rehabilitation Hospital; Hugo W. Moser Research Institute at Kennedy...Recruiting
-
University of HaifaMedical Corps, Israel Defense ForceCompleted
-
National Institute on Drug Abuse (NIDA)CompletedPain | Chronic Pain
-
Ayşe ARIKAN DÖNMEZNot yet recruitingDementia | Virtual Reality | Education | Nursing StudentsTurkey
-
Assistance Publique Hopitaux De MarseilleUnknownthe Treatment of DepressionFrance
-
Acibadem UniversityKartal Dr. Lütfi Kirdar City HospitalCompletedRheumatoid Arthritis | Chronic Pain | Virtual RealityTurkey
-
University of BeykentCompletedSimulation | Nasogastric TubeTurkey